ERRATA

The May 20, 2008, correspondence reply by Ferrandina et al (J Clin Oncol 26:2603, 2008) contained an error. The second sentence of the second paragraph referred to cases of platinum sensitivity occurring 6 to 12 months after therapy, whereas it should have been 7 to 12 months, as follows:

“However, it has to be pointed out that in the context of the so-called platinum sensitivity, cases relapsing **7 to 12 months** after the last administration of platinum based therapy are considered partially platinum sensitive, which corresponds, as in the case of seeing a glass half full or half empty on the basis of the own view point of each investigator, to partially platinum resistant.⁴”

DOI: 10.1200/JCO.2008.19.8614

The July 20, 2008, article by Hochster et al, entitled, “Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study” (J Clin Oncol 26:3523-3529, 2008) contained errors.

In Tables 1, 2, 3 and 4, the following abbreviations were incorrectly given and should have been:

TREE, Three Regimens of Eloxatin Evaluation; mFOLFOX6, bolus and infusion fluorouracil and leucovorin with oxaliplatin; bFOL, bolus fluorouracil and low-dose leucovorin with oxaliplatin; CapeOx, capecitabine with oxaliplatin.

In Table 4, the last column heading for the TREE-2 cohort was given as bFOL + Bev, whereas it should have been CapeOx + Bev.

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2008.19.8630

The August 20, 2008, article by Raetz et al entitled, “Reinduction Platform for Children With First Marrow Relapse in Acute Lymphoblastic Lymphoma” (J Clin Oncol 26: 3971-3978) contained an error.

The Title should have read:

“Reinduction Platform for Children With First Marrow Relapse **of** Acute Lymphoblastic **Leukemia: A Children’s Oncology Group Study**”

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2008.19.8648